Aclaris Therapeutics, Inc. — Form 10-K Summary
Business context and reporting period
Aclaris is a clinical-stage dermatology specialty pharmaceutical company with no approved products or commercial revenue. Its lead candidate, A-101 topical solution, is a high-concentration hydrogen peroxide treatment for seborrheic keratosis (SK). The filing covers the fiscal year ended December 31, 2015; the supplied period label of “2015 Q4” corresponds to the fourth quarter within this annual filing.
- Completed three Phase 2 SK trials involving more than 300 patients, with statistically significant lesion-clearing results.
- Initiated a Phase 2 trial of A-101 for common warts in December 2015.
- Licensed JAK inhibitors from Rigel and other licensors for potential alopecia areata treatments, designated A-201 and A-301.
- Completed its initial public offering in October 2015 and began trading on Nasdaq under “ACRS.”
Financial performance and position
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $15.339 million | $6.507 million | +$8.832 million |
| General and administrative expense | $5.328 million | $2.026 million | +$3.302 million |
| Total operating expenses | $20.667 million | $8.533 million | +$12.134 million |
| Net loss | $20.563 million | $8.517 million | +$12.046 million loss |
| Net loss attributable to common stockholders | $23.129 million | $10.571 million | +$12.558 million loss |
| Basic and diluted loss per share | $3.79 | $6.15 | Loss per share improved |
| Cash, cash equivalents and marketable securities | $92.038 million | $16.648 million | +$75.390 million |
| Working capital | $84.969 million | $14.883 million | +$70.086 million |
Because the company generated no revenue, gross and operating margins are not meaningful. Operating loss was $20.667 million, and accumulated deficit was $42.833 million at December 31, 2015. The filing does not identify material debt; total liabilities were $1.555 million, consisting primarily of accounts payable and accrued expenses.
Cash used in operating activities was $20.369 million, compared with $7.636 million in 2014. Investing activities used $76.951 million, primarily for purchases of marketable securities. Financing activities provided $96.414 million, including $39.864 million from Series C preferred stock and $56.550 million of net IPO proceeds. Ending cash and cash equivalents were $9.851 million, supplemented by $82.187 million of marketable securities.
Material changes versus the prior comparable period
- R&D expense more than doubled, primarily due to the $8.0 million upfront Rigel license payment, higher clinical and regulatory consulting costs, and a $0.3 million equipment impairment charge.
- G&A expense increased substantially due to higher payroll, stock-based compensation, market research, patent costs, professional fees, insurance and public-company expenses.
- The company raised $40.0 million of gross Series C preferred stock proceeds and completed the $63.25 million gross IPO, resulting in $56.55 million of net IPO proceeds.
- All outstanding preferred stock converted into 11.677 million common shares upon the IPO, eliminating preferred stock from the balance sheet.
- Stock-based compensation increased to $0.891 million from $0.027 million.
- Quarterly results were unusually concentrated in the third quarter, which included $10.640 million of operating expenses and a $10.632 million net loss, primarily reflecting licensing and related development activity.
Guidance, outlook, risks and unusual items
- In the first quarter of 2016, Aclaris initiated two blinded Phase 3 trials and one open-label Phase 3 trial of A-101 in approximately 1,000 SK patients. Subject to favorable results, management expected to submit an FDA NDA in the fourth quarter of 2016.
- Management expected Phase 2 common-wart trial results in the third quarter of 2016 and planned to submit INDs for A-201 and A-301 during 2016, with clinical trials potentially beginning in 2017.
- The company believed its December 31, 2015 cash, cash equivalents and marketable securities would fund operating and capital requirements for more than 12 months under current assumptions, including Phase 3 development, an NDA submission and the common-wart program.
- Additional funding is expected to be required for commercialization, broader pipeline development and potential acquisitions or licenses. No committed external funding source was in place.
- Key risks include failure or delay of clinical trials, regulatory non-approval, patient enrollment, adverse events, reliance on contract research organizations and manufacturers, supply interruption, intellectual-property challenges, competition, reimbursement limitations and patients’ willingness to pay out of pocket for SK procedures.
- A-101 SK treatment is expected to be largely cash-pay because third-party payors generally do not reimburse removal of non-malignant lesions.
- Material contingent obligations include up to $90 million of Rigel development milestones, up to $2.35 million of milestones under another JAK license, A-101-related milestones and royalties, and a potential supply-agreement termination fee of up to $0.4 million. These amounts were not included in the contractual-obligations table because timing and likelihood were uncertain.
- The company recorded $8.0 million of Rigel upfront consideration and $0.25 million of other JAK-license upfront consideration as R&D expense because the acquired intellectual property had no alternative future use.
- The filing reports effective disclosure controls, but no management assessment or auditor attestation of internal control over financial reporting was included because of the newly public company transition exemption.
Most important facts for investors to verify
- Phase 3 A-101 enrollment, safety, efficacy and timing of any NDA submission or regulatory response.
- Actual cash burn and whether the stated cash runway remains sufficient after Phase 3, manufacturing and commercialization spending.
- Terms, probability and timing of Rigel and other license milestones, royalties and termination rights.
- Manufacturing readiness, supply continuity for hydrogen peroxide and applicator components, and regulatory compliance of third-party manufacturers.
- Patient and dermatologist adoption assumptions, particularly the cash-pay model for SK treatment and reimbursement for common-wart procedures.
- Potential dilution from the 1.739 million outstanding stock options, 53,800 restricted stock units and future equity financing.
- Patent scope and expiration dates, including the principal A-101 patents beginning to expire in 2022 and JAK-inhibitor patents expiring between 2023 and 2030.